Unique ID issued by UMIN | UMIN000028645 |
---|---|
Receipt number | R000032723 |
Scientific Title | Test-retest reliability of a quantitative bone SPECT/CT |
Date of disclosure of the study information | 2017/09/01 |
Last modified on | 2022/03/22 12:43:45 |
Test-retest reliability of a quantitative bone SPECT/CT
Test-retest reliability of a quantitative bone SPECT/CT
Test-retest reliability of a quantitative bone SPECT/CT
Test-retest reliability of a quantitative bone SPECT/CT
Japan |
Prostate cancer
Urology | Radiology |
Malignancy
NO
To evaluate test-retest reliability of the quantitative value measured by quantitative bone SPECT/CT
Efficacy
test-retest reliability
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Diagnosis
Device,equipment |
Bone scintigraphy and SPECT/CT
20 | years-old | <= |
Not applicable |
Male
#1 Written informed consent was acquired
#2 Twenty years or older
#3 Prostate cancer was diagnosed or suspected
#4 Bone scintigraphy was performed or planned
#5 Second bone scintigraphy can be performed in 4-10 days after the first bone scan numbered #4
#1 Unable to keep supine position for 1 hour
#2 Anti-cancer drug, hormone drug, radionuclide treatment or radiation therapy for bone lesion was planned during 2 bone scans
#3 Person in charge considered inappropriate to include to this study
30
1st name | Tomohiko |
Middle name | |
Last name | Yamane |
Saitama Medical University International Medical Center
Nuclear Medicine
3501298
Yamane 1397-1, Hidaka
042-984-4111
yamane_t@saitama-med.ac.jp
1st name | Yamane |
Middle name | |
Last name | Tomohiko |
Saitama Medical University International Medical Center
Nuclear Medicine
3501298
Yamane 1397-1, Hidaka
042-984-4111
yamane_t@saitama-med.ac.jp
Saitama Medical University
Saitama Medical University International Medical Center
Self funding
Saitama Medical University International Medical Center IRB
Yamane 1397-1, Hidaka
042-984-4111
chikens@saitama-med.ac.jp
NO
2017 | Year | 09 | Month | 01 | Day |
https://link.springer.com/article/10.1007/s12149-020-01568-2
Published
https://link.springer.com/article/10.1007/s12149-020-01568-2
13
The ICCs were 0.968 [95% CI (0.959, 0.975)] for SUVmax and 0.976 [95% CI (0.969, 0.981)] for SUVpeak. The RCs of the relative difference were 30.7% for SUVmax and 27.6% for SUVpeak, and the MAPDs of all lesions were 12.3% for SUVmax and 11.5 for SUVpeak. The RCs and the MAPDs showed comparable value with the previous report regarding repeatability studies on PET.
2022 | Year | 03 | Month | 22 | Day |
Patients with prostate cancer planning to receive bone SPECT/CT for the evaluation of bone abnormality between August 2017 and September 2019.
Recruited patients who matched the criteria.
No adverse events
Intraclass correlation coefficient (ICC), repeatability coefficient (RC), and mean absolute percentage difference (MAPD)
Completed
2017 | Year | 09 | Month | 01 | Day |
2017 | Year | 09 | Month | 06 | Day |
2017 | Year | 09 | Month | 30 | Day |
2019 | Year | 12 | Month | 31 | Day |
2017 | Year | 08 | Month | 12 | Day |
2022 | Year | 03 | Month | 22 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032723
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |